Neurocrine Announces Conference Call And Webcast To Report Second Quarter 2017 Results

Published: Jul 31, 2017

SAN DIEGO, July 28, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report second quarter 2017 results after the Nasdaq market close on August 3, 2017. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update that day at 5:00pm Eastern Time (2:00pm Pacific Time).

Participants can access the live conference call by dialing 888-632-3381 (US) or 785-424-1678 (International) using the conference ID: NBIX. The call can also be accessed via the webcast through the Company's website at

If you are unable to attend the webcast and would like further information on this announcement, please contact the Investor Relations Department at A replay of the conference call will be available approximately one hour after the conclusion of the call by dialing 800-243-8160 (US) or 402-220-9032 (International) using the conference ID: NBIX. The call will be archived for one month.

About Neurocrine Biosciences

Neurocrine Biosciences is a San Diego based biotechnology company focused on neurologic, psychiatric and endocrine related disorders. In April of 2017, the FDA approved INGREZZA® (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD). INGREZZA is a novel, selective vesicular monoamine transporter 2 (VMAT2) inhibitor, and is the first and only FDA-approved product indicated for the treatment of adults with TD. The Company markets INGREZZA in the United States. The Company's three late-stage clinical programs are: elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc.; opicapone, a novel, once-daily, peripherally-acting, highly-selective catechol-o-methyltransferase inhibitor under investigation as adjunct therapy to levodopa in Parkinson's patients; and INGREZZA (valbenazine), a novel, once-daily, selective VMAT2 inhibitor under investigation for the treatment of Tourette syndrome.

Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at

View original content:

SOURCE Neurocrine Biosciences, Inc.

Back to news